836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

Authors :: J Kaufman
Anthony W. Tolcher
V M Jansen
Kyri Papadopoulos
Kathleen N. Moore
D L Richardson
Ding Wang
Corrine Zarwan
Charles K. Anderson
R Mosher
Deborah B. Doroshow
Erika Hamilton
Joseph Buscema
Minal A. Barve
D Jarlenski
D Huebner
Source :: Annals of Oncology. 31:S627-S628
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
Antibody-drug conjugate
business.industry
Internal medicine
medicine
Subgroup analysis
Hematology
Ovarian cancer
medicine.disease
business

Full Text Access

Tools